Thermo Fisher Scientific Adalimumab Monoclonal Antibody (15C7)

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.001-0.1 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG2b, kappa

Class

Monoclonal

Type

Antibody

Clone

15C7

Immunogen

Adalimumab

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab is a TNF-inhibiting, anti-inflammatory, biologic medication. It binds to tumor necrosis factor-alpha (TNFalpha), which normally binds to TNFalpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFalpha, adalimumab reduces this inflammatory response. Because TNFalpha is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections.

Target Information

Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNF alpha (tumor necrosis factor-alpha), and blocks its interaction with TNF alpha receptors, reducing the inflammatory response of autoimmune diseases.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.